GoodRx stock plummets 18% on Q3 revenue miss & weak guidance

GoodRx Holdings (GDRX) shares closed with more than an 18% loss on Thursday after the company reported its Q3 results.

Revenue for the quarter came in at $180 million (down 4% year-over-year), missing the consensus estimate of $188.52M, primarily due to a $10M contract termination payment to a client in Q3, which was recognized as a reduction of revenue, partially offset by organic growth in prescription transactions revenue.

Q3 EPS was $0.06, in line with the Street estimates.

For Q4/23, the company expects revenue to be in the range of $188-$194M, compared to the consensus of $192.7M.

For the full year, the company sees revenue at $742-$748M, compared to the consensus estimate of $754.9M.